苏黄止咳胶囊治疗慢性阻塞性肺疾病有效性与安全性的Meta分析  

Meta-analysis of efficacy and safety of Suhuang Zhike Capsules in treatment of chronic obstructive pulmonary disease

作　　者：赵锐恒 韩静 韩泽璐 张舒华 林江涛[2] ZHAO Rui-heng;HAN Jing;HAN Ze-lu;ZHANG Shu-hua;LIN Jiang-tao(Graduate School,Beijing University of Chinese Medicine,Beijing 100029,China;Department of Respiratory and Critical Care,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]北京中医药大学研究生院,北京100029 [2]中日友好医院呼吸与危重科,北京100029

出　　处：《中国中药杂志》2022年第4期1095-1102,共8页China Journal of Chinese Materia Medica

基　　金：国家中医药管理局标准化项目(SATCM-2015-BZ402)。

摘　　要：为评价苏黄止咳胶囊治疗慢性阻塞性肺疾病的有效性和安全性,检索中、英文数据库,检索时间为建库至2021年7月,筛选符合标准的苏黄止咳胶囊治疗慢性阻塞性肺疾病的随机对照试验(RCTs),共检索到130项研究,筛选后获得符合标准的RCTs共12项,1159例患者(试验组579例,对照组580例),男性728例(62.8%),女性431例(37.2%)。Meta分析结果显示,西药常规治疗联合苏黄止咳胶囊与西药常规治疗相比,可显著提高临床总有效率(OR=4.31,95%CI[2.88,6.46],Z=7.08,P<0.00001)、1秒用力呼吸容积(FEV1)(SMD=0.88,95%CI[0.60,1.16],Z=6.24,P<0.00001)、用力肺活量(FVC)(SMD=0.96,95%CI[0.38,1.55],Z=3.22,P=0.001)、1秒率(FEV1/FVC%)(SMD=0.85,95%CI[0.51,1.19],Z=4.92,P<0.00001)、最大自主通气量(MVV)(SMD=0.61,95%CI[0.39,0.83],Z=5.40,P<0.00001),差异均具有统计学意义。在残气量/肺总量比值(RV/TLC)(SMD=-0.93,95%CI[-3.38,1.53],Z=0.74,P=0.46)、不良反应(OR=1.39,95%CI[0.76,2.56],Z=1.07,P=0.28)方面,2组差异无统计学意义。结果表明,西药常规联合苏黄止咳胶囊治疗慢性阻塞性肺疾病可提高临床疗效,改善肺功能,安全性良好,但由于纳入的研究方法学质量参差不齐、样本量小、结局指标不一致,因此仍然需要更多高质量、多中心、大样本的RCTs证据支持。This study aims to evaluate the effectiveness and safety of Suhuang Zhike Capsules in treating chronic obstructive pulmonary disease.The Chinese and English databases were searched(from the establishment to July 2021)for randomized controlled trials(RCTs)on the treatment of chronic obstructive pulmonary disease with Suhuang Zhike Capsules,yielding 130 articles and finally 12 eligible RCTs.The 12 RCTs enrolled a total of 1159 patients(579 in experimental group,580 in control group),with 728 males(62.8%)and 431 females(37.2%).Meta-analysis showed that the conventional western medicine combined with Suhuang Zhike Capsules increased clinical efficacy(OR=4.31,95%CI[2.88,6.46],Z=7.08,P<0.00001),forced expiratory volume in one second(FEV1)(SMD=0.88,95%CI[0.60,1.16],Z=6.24,P<0.00001),forced vital capacity(FVC)(SMD=0.96,95%CI[0.38,1.55],Z=3.22,P=0.001),forced vital capacity rate of one second(FEV1/FVC%)(SMD=0.85,95%CI[0.51,1.19],Z=4.92,P<0.00001),and maximum voluntary ventilation(MVV)(SMD=0.61,95%CI[0.39,0.83],Z=5.40,P<0.00001)compared with the conventional western medicine alone.The differences in residual volume/total lung capacity(RV/TLC)(SMD=-0.93,95%CI[-3.38,1.53],Z=0.74,P=0.46)and adverse reactions(OR=1.39,95%CI[0.76,2.56],Z=1.07,P=0.28)are insignificant.The study showed that the conventional western medicine combined with Suhuang Zhike Capsules could improve clinical efficacy and lung functions in the treatment of chronic obstructive pulmonary disease.In addition,the combination had been verified to be safe.However,in view of the uneven method quality,small sample size,and inconsistent outcome indicators of the included studies,higher-quality,multi-center,and large-sample RCTs are needed for further verification.

关 键 词：苏黄止咳胶囊 慢性阻塞性肺疾病 有效性 安全性 META分析 

分 类 号：R259[医药卫生—中西医结合]